Description
Cambrex is a global CDMO with 45 years of experience, offering drug substance, drug product, and analytical services. With 2,000+ experts across North America and Europe, it offers continuous flow synthesis, controlled substances, peptide synthesis, solid-state science, and HPAPIs. In 2025, it announced a $120M investment to expand US API manufacturing capacity, including large-scale liquid phase peptide manufacturing in Charles City, Iowa.